NO991565L - 1,4-disubstituerte piperaziner - Google Patents

1,4-disubstituerte piperaziner

Info

Publication number
NO991565L
NO991565L NO991565A NO991565A NO991565L NO 991565 L NO991565 L NO 991565L NO 991565 A NO991565 A NO 991565A NO 991565 A NO991565 A NO 991565A NO 991565 L NO991565 L NO 991565L
Authority
NO
Norway
Prior art keywords
insulin
disubstituted piperazines
treatment
present
hyperalgesic
Prior art date
Application number
NO991565A
Other languages
English (en)
Norwegian (no)
Other versions
NO991565D0 (no
Inventor
Rolf Hohlweg
Peter Madsen
Rgensen Tine Krogh J
Knud Erik Andersen
Brett Watson
Zdenek Polivka
Otylie Konigova
Alexandra Silhankova
Vladimir Valenta
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO991565D0 publication Critical patent/NO991565D0/no
Publication of NO991565L publication Critical patent/NO991565L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/76—Ring systems containing bridged rings containing three rings containing at least one ring with more than six ring members
    • C07C2603/78—Ring systems containing bridged rings containing three rings containing at least one ring with more than six ring members containing seven-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
NO991565A 1996-10-04 1999-03-30 1,4-disubstituerte piperaziner NO991565L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK109096 1996-10-04
PCT/DK1997/000422 WO1998015548A1 (en) 1996-10-04 1997-10-02 1,4-disubstituted piperazines

Publications (2)

Publication Number Publication Date
NO991565D0 NO991565D0 (no) 1999-03-30
NO991565L true NO991565L (no) 1999-06-04

Family

ID=8100883

Family Applications (1)

Application Number Title Priority Date Filing Date
NO991565A NO991565L (no) 1996-10-04 1999-03-30 1,4-disubstituerte piperaziner

Country Status (20)

Country Link
US (4) US5916889A (pt)
EP (1) EP0934312B1 (pt)
JP (1) JP2001502307A (pt)
KR (1) KR20000048899A (pt)
CN (1) CN1088459C (pt)
AT (1) ATE234831T1 (pt)
AU (1) AU740662B2 (pt)
BR (1) BR9712196A (pt)
CA (1) CA2267835A1 (pt)
CZ (1) CZ114099A3 (pt)
DE (1) DE69720021T2 (pt)
DK (1) DK0934312T3 (pt)
ES (1) ES2194217T3 (pt)
HU (1) HUP0000090A3 (pt)
IL (1) IL129123A (pt)
NO (1) NO991565L (pt)
PL (1) PL188338B1 (pt)
RU (1) RU2188197C2 (pt)
WO (1) WO1998015548A1 (pt)
ZA (1) ZA978864B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001501629A (ja) * 1996-10-04 2001-02-06 ノボ ノルディスク アクティーゼルスカブ Ｎ―置換アザ複素環式化合物
US6613905B1 (en) * 1998-01-21 2003-09-02 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US7045519B2 (en) * 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
JP4533534B2 (ja) 1998-06-19 2010-09-01 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド グリコーゲンシンターゼキナーゼ３のインヒビター
US7541365B2 (en) 2001-11-21 2009-06-02 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US20040038861A1 (en) * 2001-11-26 2004-02-26 Cooper Garth J. S. Methods and compositions for normalizing lipid levels in mammalian tissues
TWI291467B (en) 2002-11-13 2007-12-21 Millennium Pharm Inc CCR1 antagonists and methods of use therefor
AU2005286593A1 (en) * 2004-09-23 2006-03-30 Reddy Us Therapeutics, Inc. Novel pyridine compounds, process for their preparation and compositions containing them
FR2885616B1 (fr) * 2005-05-12 2007-06-22 Servier Lab Nouveaux derives de phenylpyridinylpiperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2885615B1 (fr) * 2005-05-12 2007-06-22 Servier Lab Nouveaux derives de phenylpyridinylpiperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP2009514969A (ja) 2005-11-09 2009-04-09 コンビナトアールエックス インコーポレーティッド 医学的状態を治療するための方法、組成物、およびキット
EP2420239B1 (en) * 2007-04-13 2015-01-14 Southern Research Institute Clomipramine as anti-angiogenic agent
CN103086898B (zh) * 2012-07-11 2015-04-08 山东道可化学有限公司 二苯胺或其环上取代的衍生物的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL102488C (pt) * 1957-07-18
GB1013901A (en) * 1962-01-26 1965-12-22 Kefalas As Dihydroanthracene, dibenzocycloheptadiene and dibenzocycloheptatriene derivatives
FR88751E (pt) * 1963-07-09 1967-06-07
US3435073A (en) * 1966-04-19 1969-03-25 Colgate Palmolive Co 5-(n-benzyl-n-lower alkylaminoalkylene)-5h-dibenzo(a,d)cycloheptenes
GB1347935A (en) * 1971-04-10 1974-02-27 Yoshitomi Pharmaceutical Piperazine derivatives methods for their production and phar maceutical compositions containing them
FR2186249A1 (en) * 1972-05-31 1974-01-11 Synthelabo Phenyl piperazinoalkyl (dihydro)dibenzazepines - antidepressants having low toxicity
HU174126B (hu) * 1977-08-02 1979-11-28 Egyt Gyogyszervegyeszeti Gyar Sposob poluchenija novykh proizvodnykh dibenzo-kvadratnaja skobka-d,g-kvadratnaja skobka zakryta-kvadratnaja skobka-1,3,6-kvadratnaja skobka zakryta-dioksazocina
ES524680A0 (es) * 1983-08-02 1984-12-16 Espanola Farma Therapeut Procedimiento de obtencion de nuevos compuestos derivados de la difenil-metilen-etilamina.
AU612437B2 (en) * 1987-12-14 1991-07-11 Kyowa Hakko Kogyo Co. Ltd. Tricyclic compounds
ZA914764B (en) * 1990-06-22 1992-03-25 Schering Corp Bis-benzo or benzopyrido cyclohepta piperidene,piperidylidene and piperazine compounds,compositions and methods of use
MY113463A (en) * 1994-01-04 2002-03-30 Novo Nordisk As Novel heterocyclic compounds
UA54385C2 (uk) * 1995-04-07 2003-03-17 Ново Нордіск А/С N-заміщені азагетероциклічні карбонові кислоти та їх ефіри, спосіб їх одержання, фармацевтична композиція та спосіб лікування
EP0851865B1 (en) * 1995-09-19 2002-07-17 Novo Nordisk A/S 12H-Dibenzo[d,g][1,3]dioxocine derivatives

Also Published As

Publication number Publication date
DE69720021D1 (de) 2003-04-24
US5916889A (en) 1999-06-29
DK0934312T3 (da) 2003-07-21
KR20000048899A (ko) 2000-07-25
HUP0000090A3 (en) 2002-01-28
ATE234831T1 (de) 2003-04-15
PL332597A1 (en) 1999-09-27
IL129123A0 (en) 2000-02-17
AU740662B2 (en) 2001-11-08
CN1088459C (zh) 2002-07-31
HUP0000090A2 (hu) 2001-04-28
RU2188197C2 (ru) 2002-08-27
BR9712196A (pt) 1999-08-31
IL129123A (en) 2004-07-25
EP0934312A1 (en) 1999-08-11
US6040302A (en) 2000-03-21
US6004961A (en) 1999-12-21
WO1998015548A1 (en) 1998-04-16
ZA978864B (en) 1998-04-06
CA2267835A1 (en) 1998-04-16
NO991565D0 (no) 1999-03-30
US6133268A (en) 2000-10-17
AU4377297A (en) 1998-05-05
JP2001502307A (ja) 2001-02-20
PL188338B1 (pl) 2005-01-31
CZ114099A3 (cs) 1999-09-15
CN1234799A (zh) 1999-11-10
EP0934312B1 (en) 2003-03-19
ES2194217T3 (es) 2003-11-16
DE69720021T2 (de) 2004-02-05

Similar Documents

Publication Publication Date Title
DK0934312T3 (da) 1,4-disubstituerede piperaziner
ATE469161T1 (de) Pyrazolderivat, dieses enthaltende medizinische zusammensetzung, medizinische verwendung davon, und zwischenprodukt für dessen herstellung
DK0738262T3 (da) Hidtil ukendte heterocykliske forbindelser
IS8058A (is) Sýklísk súlfónamíð til að hamla gamma seytiasa
BR0009563A (pt) Inibidores de ap2 de bifenilas contendo heterocìclico e método
NO20045281L (no) Tiazolidinoner og anvendelse derav som polo-lignende kinaseinhibitorer
BRPI0111639B8 (pt) uso de uma molécula de ácido oligodeoxinucléico imunoestimulatório e composição farmacêutica.
MY132056A (en) Methods of inhibiting physiological conditions associated with an excess of neuropeptide y.
BR0303093A (pt) Barras de limpeza contendo elementos discretos
BR9712202A (pt) Composto, processo para preparar o mesmo, composicão farmacêutica, processo para o tratamento de inflamacão neurogênica em um indivíduo em necessidade deste tratamento, e, uso do composto.
MX9707531A (es) Nuevos compuestos heterociclicos.
HUP0105039A2 (hu) Fungicid hatású propargil-éter-származékok, előállításuk és alkalmazásuk
ES2060173T3 (es) Derivados de lisolecitina para el tratamiento de enfermedades autoinmunologicas.
AR001838A1 (es) Derivados de azacicloal canos utiles para el tratamiento de la obesidad diabetes e hiperglucemia procedimiento para prepararlos composiciones farmacéuticas que los contienen y aplicación de dichos derivados en la preparación de dichas composiciones
AR002741A1 (es) Benciloxicarbonilguanidinas sustituidas, procedimiento para su preparacion, su utilizacion como medicamento o agente de diagnostico asi como medicamentoque las contiene
ATE205489T1 (de) N-substituierte azaheterocyclische carbonsäuren und ihre alkylester
WO1999047517A8 (en) Novel heterocyclic compounds
HUP0101041A2 (hu) Fungicid hatású N-szulfonil és N-szulfinil-fenil-glicinamid-származékok, intermedierjeik, előállításuk és alkalmazásuk
EA200400709A1 (ru) Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1
KR950016739A (ko) 강박관념 질환 및 소모성 질환을 억제하는 방법
AR037963A1 (es) Piperidin-2,6-diona sustituida con heterociclo en la posicion 3, procedimiento para prepararla, medicamento que la contiene y su uso para preparar este ultimo
ATE205833T1 (de) Heterocyclische verbindungen für diabetebehandlung
TH42375A (th) อนุพันธ์ 2-(พิวริน-9-อิล)-เททราไฮโดรฟิวแรน-3,4-ไดออล
TH41641A (th) สารผสมร่วมของโปรซิสเตอีนกับโพลีออล
SE9904416D0 (sv) Crystalline form

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application